Abstract
Encorafenib and cetuximab is efficient in anti-EGFR-naïve patients (pts) with BRAFV600E mutated (BRAFm) metastatic colorectal cancer (mCRC) after failure of one or two prior lines of treatment (BEACON trial). However to date, the efficacy of BRAF inhibitors in combination with anti-EGFRs (B+E) in patients (pts) previously treated with an anti-EGFR agent has never been reported.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
